221 results
Page 3 of 12
6-K
1t0ihhlzl6s 7ykbzd
30 May 23
Current report (foreign)
6:20am
6-K
EX-99.1
fhcbrsx9lbzw
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
jfzvm
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
8a431xv1ivhzt osiq
30 May 23
Current report (foreign)
6:11am
6-K
e3xbc7ikfye93hu4i
17 May 23
Current report (foreign)
6:02am
6-K
a3wh7
11 May 23
Current report (foreign)
6:10am
6-K
7uyir83 126f9e
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
jg2os yp1
11 May 23
Current report (foreign)
6:07am
6-K
ab0 kraitk
30 Mar 23
Current report (foreign)
6:19am
6-K
o3jqdm466soi2odv9
21 Dec 22
Current report (foreign)
6:01am
6-K
EX-99.1
pj4gmf
21 Dec 22
Current report (foreign)
6:01am
6-K
EX-99.1
cdb8a7yymca
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
hvr0p7h8 z354
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
8sf1be g66y
8 Dec 22
Current report (foreign)
6:46am
6-K
0ap4c8zd7
4 Nov 22
Current report (foreign)
6:01am
6-K
EX-99.1
527guf7frzi2 78
27 Oct 22
Current report (foreign)
6:01am
6-K
xz398kj2s
27 Oct 22
Current report (foreign)
6:01am
6-K
uunzyorr
14 Oct 22
Current report (foreign)
7:36am
6-K
ozg sbp37
4 Oct 22
Current report (foreign)
6:06am
6-K
EX-99.1
qny4l
23 Aug 22
Current report (foreign)
6:13am